New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
11:44 EDTMYL, KKR, GSKMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
News For MYL;GSK;KKR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 23, 2015
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 22, 2015
19:03 EDTKKRCVC, Canadian Pension to acquire Petco for $4.7B, Bloomberg says
Subscribe for More Information
November 20, 2015
07:32 EDTMYLMylan completes acquisition of certain businesses from Famy Care
Subscribe for More Information
November 19, 2015
15:29 EDTMYLMylan confirms first-to-file patent challenge relating to Delzicol
Subscribe for More Information
13:52 EDTMYLMylan announces U.S. launch of generic Adderall tablets
Subscribe for More Information
06:49 EDTKKRCiti closes out long KKR, short Och-Ziff pair trade
Subscribe for More Information
November 18, 2015
16:24 EDTKKRBlackstone, Carlyle, KKR potential buyers of Armacell, Reuters says
Britain's Charterhouse has established a Friday deadline for bids on its insulation materials company Armacell, which may be valued at up to $1.06B, reports Reuters, citing sources. The business has attracted interest from private equity firms, with Blackstone (BX), Carlyle (CG), and KKR (KKR) "cited as potential buyers," according to the report. Reference Link
08:22 EDTMYLMylan resinstated with an Overweight at JPMorgan
Subscribe for More Information
08:11 EDTGSKIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
06:02 EDTMYLPerrigo upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
November 17, 2015
10:11 EDTMYLOptions with decreasing implied volatility
Subscribe for More Information
07:48 EDTKKRBofa/Merrill to hold a conference
Banking & Financial Services Conference 2015 is being held in New York on November 17-18.
07:34 EDTMYLMylan launches Almotriptan Tablets USP in the U.S.
Subscribe for More Information
05:21 EDTKKRKKR invests in Avendus Capital
Subscribe for More Information
November 16, 2015
11:42 EDTMYLMylan announces $1B share repurchase plan
Mylan announced that the Board of Directors of Mylan has authorized share repurchases by the company of its ordinary shares in an amount up to $1B, either in the open market through privately-negotiated transactions or in one or more self tender offers. The repurchase program does not obligate the company to acquire any particular amount of ordinary shares. The authorization expires on August 27, 2016.
08:04 EDTKKRSignostics announces investment, capital partnership with KKR
Subscribe for More Information
08:00 EDTKKRKKR to invest $35M in Signostics, Reuters says
Subscribe for More Information
07:40 EDTMYLMylan launches generic Viramune XR ER tablets, 100mg
Subscribe for More Information
07:32 EDTMYLMylan launches generic GLUCOTROL XL tablets
Mylan (MYL) announced the U.S. launch of Glipizide Extended-release Tablets, 5 mg and 10 mg, the generic version of Pfizer's (PFE) GLUCOTROL XL. Mylan received final approval from the FDA for its Abbreviated New Drug Application for this product, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide Extended-release Tablets, 5 mg, and 10 mg, had U.S. sales of approximately $70.7 million for the 12 months ending September 30, 2015, according to IMS Health.
07:16 EDTMYLHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use